Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832429 · ClinicalTrials.gov registry record · Phase 2
Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00832429: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00832429 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00832429, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph nodes.
Interventions
- PROCEDURE Sentinel Lymph Node Biopsy
- PROCEDURE Lymph Node Mapping
- DRUG Technetium Tc-99m Sulfur Colloid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-02-25 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00832429
The ClinicalTrials.gov registry entry for NCT00832429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sentinel Lymph Node Biopsy is the first listed.
NCT00832429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00832429 about?
NCT00832429 is a clinical study titled "Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid". This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph node...
What is the current status of trial NCT00832429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-02-25. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT00832429?
The interventions under investigation include: Sentinel Lymph Node Biopsy (PROCEDURE), Lymph Node Mapping (PROCEDURE), Technetium Tc-99m Sulfur Colloid (DRUG).
Who is sponsoring clinical trial NCT00832429?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.